Viridian Therapeutics (VRDN)
(Real Time Quote from BATS)
$17.23 USD
-0.06 (-0.35%)
Updated Jul 30, 2024 10:26 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VRDN 17.23 -0.06(-0.35%)
Will VRDN be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for VRDN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRDN
Strength Seen in Viridian Therapeutics (VRDN): Can Its 8.7% Jump Turn into More Strength?
Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug
VRDN: What are Zacks experts saying now?
Zacks Private Portfolio Services
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81%
Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Tops Revenue Estimates
Other News for VRDN
Top 3 Health Care Stocks You May Want To Dump This Quarter
Jefferies healthcare analyst holds an analyst/industry conference call
3 Biotech Names With Potential Catalysts By Year End
Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
Viridian Therapeutics completes enrollment in THRIVE-2 trial